Drug Recall: Montelukast Sodium Tablets Due to Manufacturing Deviations
Direct Rx is recalling Montelukast Sodium 10 mg tablets nationwide due to manufacturing process deviations. The voluntary recall affects approximately 508 bottles distributed across the United States.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall initiated by the manufacturer for manufacturing process deviations, with no specific identified product defect. The voluntary nature of the recall supports a Moderate severity rating.
Plain-English summary
Direct Rx is recalling Montelukast Sodium Tablets, USP, 10 mg distributed nationwide in the United States. The recall affects 30-count bottles (NDC 61919-0009-30) and 90-count bottles (NDC 61919-0009-90) packaged and distributed by Direct Rx in Dawsonville, Georgia. Multiple lot codes are affected with expiration dates ranging from December 2023 through July 2025.
The recall was initiated due to current Good Manufacturing Practice (cGMP) deviations identified during manufacturing. This is a voluntary, firm-initiated recall classified as FDA Class II.
Approximately 13 units of the 30-count bottles and 495 units of the 90-count bottles were distributed. Patients using this medication should consult their healthcare provider or pharmacist regarding their current supply and whether any action is needed.
The recall was terminated on June 17, 2024.
The recalled product
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- a) [30 count bottles] Lot
- expiry: 20JU2211
- exp 5/31/2024
- b) [90 count bottles] Lot
- expiry: 25JU2128
- exp 12/31/2023
- 13SE2132
- 25JU2133
- 16JU2127
- 18MY2126
- 10JU2111
- 14SE2111
- exp 1/31/2024
- 14JY2115
- 25OC2113
- exp 2/29/2024
- 21SE2227
- 10DE2123
- exp 3/31/2024
- 22NO2115
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 11 recalled by Direct Rx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same manufacturer · Direct Rx
See all →- ModerateDuloxetine 30 mg capsules recalled for impurity above FDA limits
FDA (Drugs) · 2026-07-01
- HighDuloxetine delayed-release capsules exceed the interim nitrosamine impurity limit
FDA (Drugs) · 2025-08-13
- HighDirect Rx duloxetine 30 mg capsules exceed the interim nitrosamine limit
FDA (Drugs) · 2025-08-13
- ModerateCiprofloxacin Ophthalmic Solution Recalled for Defective Container Cap
FDA (Drugs) · 2025-04-23
- HighGeneric Ibuprofen 800mg Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-11-13
Same hazard · manufacturing deviation
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06